Phase 3
-
Spine
Spine BioPharma, Inc. Announces Completion of Enrollment for Phase 3 Clinical Trial of SB-01 to Address Chronic Low Back Pain
NEW YORK, September 24, 2024 –(BUSINESS WIRE)– Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for…
Read More » -
Spine
DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease
Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials Achieves alignment with FDA on Chemistry,…
Read More » -
Recon
Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a Single-dose Femoral Nerve Block in the Adductor Canal for Total Knee Arthroplasty
Study achieved primary and key secondary endpoints of statistically significant reductions in postsurgical pain and opioid consumption through 96 hours.…
Read More » -
Spine
Spine BioPharma Announces First Patient Treated in U.S. Phase 3 Clinical Study
SB-01 For Injection Offers New Potential Treatment for Patients Sufferingfrom Chronic Low Back Pain NEW YORK, September 7, 2022 – OrthoSpineNews…
Read More » -
Hospitals
Histogenics Corporation Announces Amendment to NeoCart® Phase 3 Clinical Trial Enrollment Criteria
WALTHAM, Mass., Dec. 21, 2015 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and…
Read More »